MILWAUKEE--(BUSINESS WIRE)--BloodCenter of Wisconsin today announced the availability of BCR-ABL Kinase Domain Mutation Analysis, a new DNA sequencing assay designed to help oncologists develop appropriate therapeutic strategies tailored to the specific needs of patients with chronic myeloid (or myelogenous) leukemia (CML).
